The dominant theory in neuroscience has been that the sensory processing circuits in our brain are finalized in early childhood and fixed afterward. A recently published study, however, overturned ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

Keck Medicine of USC researchers have reported striking early results from a clinical trial that could reshape treatment for one of the deadliest brain cancers.

A single genetic “switch” may be the secret to how the body’s cleanup crew grows up and keeps our organs running smoothly.

A fleeting DNA fold called i‑DNA can switch cancer‑related genes on and off, revealing a hidden structural weak point that ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast ...

FILE - Ukrainian children play at an abandoned checkpoint in Kherson, southern Ukraine, Wednesday, Nov. 23, 2022.

His remark was pointed, and Samar clearly knew it. Her fiancé used to post updates on social media as though he were writing ...